MOM-4 Inhibitors
Chemical inhibitors of MOM-4 function through various mechanisms to impede its activity within cellular signaling pathways. Staurosporine, a broad-spectrum kinase inhibitor, targets multiple protein kinases, including those associated with the activation of MOM-4. By inhibiting these kinases, Staurosporine can prevent the phosphorylation events that are essential for MOM-4 signaling activities. Similarly, LY294002 and Wortmannin are both inhibitors of PI3K, a kinase that operates upstream of MOM-4. By blocking PI3K activity, these inhibitors can reduce the production of PIP3, a critical lipid molecule in the signaling cascade, ultimately decreasing the activation of MOM-4. U0126 and PD98059, both selective inhibitors of MEK1/2, as well as PD0325901, a potent MEK inhibitor, can suppress the upstream activation of the ERK pathway, which can be linked to the regulation of MOM-4. This leads to a decrease in MOM-4 activity by limiting the activation signals that typically come from the ERK pathway.
In addition to these inhibitors, SP600125, which targets JNK, and SB203580, which targets p38 MAP kinase, can disrupt the activation of transcription factors and stress response pathways, respectively, that may regulate the activation state of MOM-4. Rapamycin, an mTOR inhibitor, acts within the PI3K/AKT pathway that can intersect with MOM-4's regulatory network, thereby reducing the signaling that contributes to MOM-4 activity. PP2, a Src family kinase inhibitor, and PF-562271, a FAK inhibitor, disrupt signaling pathways that are important for various cellular processes, potentially leading to a decrease in the activation and function of MOM-4. BIX02189 specifically inhibits MEK5, which is involved in the ERK5 pathway. By inhibiting this kinase, the signaling that may influence MOM-4 activity via the ERK5 pathway is impeded. Collectively, these chemical inhibitors act on distinct kinases and pathways that converge on or regulate MOM-4, resulting in the downregulation of its activity within cells.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent kinase inhibitor that inhibits multiple protein kinases, including those related to MOM-4 signaling pathways like MAPK, which could lead to functional inhibition of MOM-4 by preventing its activation or phosphorylation necessary for its kinase activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a phosphoinositide 3-kinase (PI3K) inhibitor. Since PI3K signaling can be upstream of MOM-4 in certain pathways, its inhibition could reduce the phosphorylation and activity of MOM-4 by limiting the production of PIP3, which is critical for some signaling cascades that activate MOM-4. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, which are upstream kinases in the MAPK/ERK pathway. By inhibiting MEK1/2, U0126 can reduce the activation of ERK, which might be an upstream regulator of MOM-4, leading to its functional inhibition. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which can be involved in pathways that regulate MOM-4 activity. Inhibition of JNK could lead to decreased activation of transcription factors that are necessary for MOM-4 function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is an inhibitor of p38 MAP kinase, which is implicated in stress and inflammatory responses and might interact with MOM-4's pathway. Inhibiting p38 MAP kinase could prevent the activation of MOM-4 that is mediated through this stress response pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K, like LY294002. It inhibits the kinase activity of PI3K, which could decrease the activation of downstream signaling molecules that are involved in the pathway of MOM-4, thus inhibiting MOM-4 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective inhibitor of MEK, which works upstream of ERK. Its inhibition of MEK could decrease ERK activation, potentially leading to a reduction in MOM-4 activity if ERK is an upstream activator of MOM-4. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor. Since mTOR is part of the PI3K/AKT pathway, which may be involved in MOM-4 regulation, inhibition of mTOR could lead to a reduction in MOM-4 activity by decreasing the signaling through this pathway. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a Src family kinase inhibitor. Src kinases can be involved in multiple signaling pathways that may regulate MOM-4. Inhibition of Src could reduce the activation of pathways necessary for MOM-4 function. | ||||||
PF-562271 | 717907-75-0 | sc-478488 sc-478488A sc-478488B | 5 mg 10 mg 50 mg | $312.00 $474.00 $1124.00 | 3 | |
PF-562271 is a focal adhesion kinase (FAK) inhibitor. Since FAK signaling is important for cell motility and survival pathways, inhibiting FAK could impact signaling cascades that involve MOM-4, leading to its functional inhibition. | ||||||